Ronald A. Sherman

Bedeutung für die Hirudotherapie

Ronald Sherman is the central figure in the modern American regulatory infrastructure that enabled both medicinal maggot therapy and medicinal leech therapy to be reintroduced into mainstream United States clinical practice. The story is institutional as much as scientific. Through the 1990s, Sherman led the American clinical and research effort to revive maggot debridement therapy for chronic wounds, demonstrating in multiple case series and small trials that medical-grade Lucilia sericata larvae produced superior debridement of necrotic tissue compared with conventional surgical or enzymatic methods. The clinical work was successful, but the regulatory path was unclear: was a living organism a drug, a biologic, a device, or something entirely new? The answer that Sherman and his FDA counterparts negotiated through the late 1990s and early 2000s was that medicinal maggots could be regulated as a Class II medical device under the 510(k) substantial-equivalence pathway. In January 2004, the FDA cleared Monarch Labs's medicinal maggots as the first living organism approved as a medical device in United States history. The precedent was decisive: just five months later, in June 2004, Ricarimpex SAS obtained 510(k) clearance K040187 for Hirudo medicinalis (later corrected to Hirudo verbana following Siddall's 2007 species work) as the second living organism approved as a medical device. Without Sherman's prior regulatory work, the leech-clearance path would have been substantially more difficult. Sherman's broader vision — articulated through his founding of the International Biotherapy Society and the BioTherapeutics Education and Research Foundation — is that biotherapy, the medicinal use of living organisms, constitutes a coherent clinical discipline that extends beyond any single organism to include maggots, leeches, medicinal helminths, ichthyotherapy, and apitherapy. The American Society of Hirudotherapy considers him the patron of the regulatory and institutional infrastructure within which contemporary American leech therapy operates. His name appears in the leech-therapy literature less often than the names of leech specialists themselves, but his work on the FDA pathway is one of the indispensable preconditions of contemporary United States hirudotherapy practice.